Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AM...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Cell Mol Med
Main Authors: Gao, Jun, Liu, Yang, Han, Gaijing, Deng, Kan, Liu, Xiaohai, Bao, Xinjie, Feng, Ming, Yao, Yong, Lian, Wei, Xing, Bing, Lv, Xiang, Wang, Renzhi
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://ncbi.nlm.nih.gov/pubmed/30334324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13963
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki